KLF5 and colorectal carcinoma: Among many examples, ML264, a KLF5 inhibitor, improved CRC organoid sensitivity to oxaliplatin [161], AY9944 and GANT61 Hedgehog pathway inhibitors reduced CRC organoid viability in combination with 5-FU or irinotecan [162] and cholesterol biosynthesis inhibitors enhanced the anticancer activity of fasting [163].